Tiger Brokers

BUZZ-Revolution jumps after US FDA adds its drug under new fast-track process

Reuters
Oct 17
BUZZ-Revolution jumps after US FDA adds its drug under new fast-track process

** Shares of drug developer Revolution Medicines RVMD.O up 7.7% to $53.51 premarket

** U.S. FDA announced nine products, including RVMD's daraxonrasib for pancreatic cancer, under new fast-track review process

** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months

** Brokerage Oppenheimer thinks daraxonrasib's first approval could come as early as mid-2026

** Eli Lilly's LLY.N experimental weight-loss pill, orforglipron, was expected to be included in the list

** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered

** LLY shares down 4.2% premarket

** YTD, up to last close, RVMD up 13.6% vs LLY's 6.1% rise

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10